Q3 2025 · 13F-HR
EcoR1 Capital, LLCholdings as filed
Filed 2025-11-14 · accession 0000935836-25-000671
$2.08B
Reported value
30
Positions
2025-09-30
Period end
The Brief · EcoR1 Capital, LLC · Q3 2025
AI · grounded in 13F
EcoR1 Capital, LLC established a new position in ZYME valued at $392.3M. The fund also initiated new stakes in ANAB for $241.3M and QURE for $232.8M. Other new additions include JAZZ at $224.9M and CRNX at $178.6M. Total assets under management stand at $2.1B across 30 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 98985Y108 | ZYME | ZYMEWORKS INC | $392.3M | 18.8% | 22,970,388 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $241.3M | 11.6% | 7,880,094 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $232.8M | 11.2% | 3,988,971 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $224.9M | 10.8% | 1,706,469 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $178.6M | 8.57% | 4,288,120 | Common | SOLE |
| H17182108 | CRSP | CRISPR THERAPEUTICS AG | $90.0M | 4.32% | 1,389,276 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $89.3M | 4.29% | 10,630,736 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $80.7M | 3.87% | 6,728,116 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $78.0M | 3.74% | 3,447,156 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $72.1M | 3.46% | 6,144,767 | Common | SOLE |
| 36315X101 | LKFT | GALAPAGOS NV | $57.7M | 2.77% | 1,667,119 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $47.8M | 2.29% | 4,079,415 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $44.1M | 2.12% | 2,030,544 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $37.2M | 1.78% | 2,123,604 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $34.4M | 1.65% | 75,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $33.3M | 1.60% | 765,000 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $32.7M | 1.57% | 2,823,126 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $22.0M | 1.06% | 1,271,342 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $15.0M | 0.72% | 500,000 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $14.7M | 0.70% | 2,625,000 | Common | SOLE |
| 59267L107 | — | METSERA INC | $14.2M | 0.68% | 271,529 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $13.3M | 0.64% | 550,000 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $8.6M | 0.41% | 1,543,326 | Common | SOLE |
| 046513206 | ATRA | ATARA BIOTHERAPEUTICS INC | $8.2M | 0.39% | 573,183 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $7.7M | 0.37% | 872,500 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $3.7M | 0.18% | 800,000 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $3.6M | 0.17% | 963,333 | Common | SOLE |
| 92915B106 | VYGR | VOYAGER THERAPEUTICS INC | $3.1M | 0.15% | 670,303 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $1.5M | 0.07% | 265,137 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $859,312 | 0.04% | 66,665 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.